HomeMost PopularWall Street Analysts' Predictions: Will Cardinal Health Stock Rise or Fall?

Wall Street Analysts’ Predictions: Will Cardinal Health Stock Rise or Fall?

Daily Market Recaps (no fluff)

always free

Cardinal Health’s Stock Performances Rise Amid Mixed Results

Dublin, Ohio-based Cardinal Health, Inc. (CAH) designs and distributes pharmaceuticals, medical and laboratory products, along with performance and data solutions for healthcare facilities. The company boasts a market cap of $30.8 billion and has a presence in over 30 countries, employing more than 48,000 individuals worldwide.

Recent Performance: Gains Over Time

Over the past year, Cardinal Health’s performance has shown it lag behind the broader market slightly. However, in 2025, the stock has risen impressively, soaring 20.5% in the last 52 weeks and 7.7% so far this year. In comparison, the S&P 500 Index ($SPX) has also reported gains, with a 20.6% increase over the past year and a 2.5% rise year-to-date.

When looking at healthcare-focused investments, Cardinal Health has exceeded the SPDR S&P Health Care Services ETF’s (XHS) 12.8% growth this past year. Nevertheless, it has not kept pace with the ETF’s 9.5% rise in 2025.

619;
www.barchart.com

Quarterly Results Show Improvement

Cardinal Health’s stock saw a slight rise after it announced better-than-expected Q2 results on January 30. The company’s quarterly revenues decreased 3.8% year-over-year to $55.3 billion, primarily due to the expiration of a major customer contract. However, adjusting for this factor, revenue increased by 16%, exceeding market expectations. Additionally, adjusted earnings per share (EPS) rose 2.1% from the previous year to $1.93, beating the consensus estimate by a significant 10.3%.

Future Earnings Outlook

Looking ahead in fiscal 2025, which concludes in June, analysts predict Cardinal’s earnings will grow by 5.6% year-over-year to $7.95 per share. The company has a strong track record, surpassing earnings expectations in each of the last four quarters.

Among the 15 analysts rating CAH’s stock, the consensus is a “Strong Buy,” comprising 11 “Strong Buy” and four “Hold” ratings.

848;
www.barchart.com

Analyst Upgrades Signal Confidence

This positive sentiment marks a notable change from three months ago, when analysts rated the stock with a “Moderate Buy” consensus. Back then, only five analysts issued “Strong Buy” recommendations, with one suggesting a “Moderate Buy” and another proposing a “Strong Sell.”

On February 5, Jefferies analyst Brian Tanquilut upgraded CAH to a “Buy” rating, raising the price target to $150.

Price Targets Indicate Upside Potential

Currently, CAH’s average price target sits at $140.81, indicating a 10.6% increase from current price levels. The highest price target from analysts reaches $156, suggesting a potential upside of 22.5%.

On the date of publication, Aditya Sarawgi did not hold any positions in the securities mentioned in this article. All information and data provided are for informational purposes only. Please review the Barchart Disclosure Policy for more details.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.

Do you want a daily market summary with no fluff?

Simple Straightforward Daily Stock Market Recaps Sent for free,every single trading day: Read Now

Explore More

Simple Straightforward Daily Stock Market Recaps

Get institutional-level analysis to take your trading to the next level, sign up for free and become apart of the community.